No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Lepu Biopharma Co., Ltd.'s (HKG:2157) Largest Shareholder, Top Key Executive Zhongjie Pu Sees Holdings Value Fall by 9.6% Following Recent Drop
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotech-B (02157.HK) has signed a CDMO service framework agreement with lepu medical technology.
On November 26, Gleam Hill reported that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, pursuant to which the company and/or its subsidiaries agreed to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
Luoping Biotechnology -B (02157.HK) intends to appoint Ernst & Young as the new auditor.
Gelonghui, November 26 - Lepu Bio-B (02157.HK) announced that PricewaterhouseCoopers has agreed to resign as the company's auditor, effective November 26, 2024. The company intends to appoint Ernst & Young as the new auditor for the 2024 fiscal year, with the term ending at the conclusion of the company's next annual general meeting of shareholders.
